Compare AbCellera Biologics Inc (ABCL) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs EPAM Systems Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while EPAM Systems Inc trades at $85.89 (market cap $4.68B). The key difference: EPAM Systems Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | EPAM | |
|---|---|---|
Market Cap | $2.35B | $4.68B |
Sector | Health | Technology |
52-Week High | $8.12 | $221.40 |
52-Week Low | $2.78 | $76.04 |
Enterprise Value | $1.99B | $3.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
EPAM Systems trades at $89.55, up 1.45% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 12.48 and P/S of 0.87, while revenue grew to $5.46B in 2025. Recent news highlights EPAM's AI partnership successes and upcoming Q2 2026 earnings, with analyst consensus strongly favoring Buy ratings (64.87%) and a $130.90 price target suggesting significant upside.
The outlook remains positive given EPAM's solid fundamentals and AI-driven growth, but risks include competitive pressures in IT services and market volatility. Institutional sentiment is bullish, though technical indicators warn of near-term resistance. Investors should weigh the strong analyst support against recent price weakness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
